Share This Page
Drug Price Trends for NDC 00395-2685
✉ Email this page to a colleague
Average Pharmacy Cost for 00395-2685
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00395-2685
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Incretin-Based Drugs: A Focus on NDC 00395-2685
Introduction
Incretin-based drugs, including those identified by the National Drug Code (NDC) 00395-2685, are a crucial class of medications used primarily for the treatment of type 2 diabetes. This article provides a comprehensive market analysis and price projections for these drugs, highlighting key drivers, market trends, and future outlook.
Global Market Size and Growth
The global incretin-based drugs market has been experiencing significant growth. As of 2022, the market size was valued at $34.4 billion and is projected to reach $73.9 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.9% from 2023 to 2032[1].
Key Drivers of Market Growth
Several factors are driving the growth of the incretin-based drugs market:
Rising Prevalence of Type 2 Diabetes
The increasing prevalence of type 2 diabetes globally is a major driver. According to the CDC, approximately 38 million Americans have diabetes, with about 90-95% of them having type 2 diabetes[1].
Expanding Indications
The expanding indications for GLP-1 agents, such as semaglutide (Ozempic® and Wegovy®), and tirzepatide (Mounjaro® and Zepbound®), are significant. These medications are not only used for diabetes and obesity but also for reducing the risk of major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease[2].
Increasing Healthcare Expenditure
Rising healthcare expenditure and the development of healthcare infrastructure, particularly in the Asia-Pacific region, are contributing to the market growth. This increased spending directly influences the demand for innovative and effective treatments like incretin-based drugs[1].
Regional Market Analysis
North America and Europe
These regions are considered lucrative markets due to well-developed healthcare infrastructure and significant awareness about diabetes management. The presence of major pharmaceutical companies and extensive marketing efforts also contribute to the growth in these regions[1][4].
Asia-Pacific
The Asia-Pacific region is anticipated to be the fastest-growing segment during the forecast period. The rising healthcare expenditure and developing healthcare infrastructure in this region are key factors driving this growth[1].
Price Projections and Inflation
Drug Price Inflation
The overall drug price inflation rate for pharmaceuticals is estimated to be 3.81% for 2025, according to Vizient's summer Pharmacy Market Outlook. This inflation rate is partly driven by the expanding indications of previously approved medications, such as semaglutide, which saw a 77% increase in spend since the summer 2023 Outlook[2].
Specific Price Trends for NDC 00395-2685
While specific price projections for NDC 00395-2685 (which corresponds to semaglutide products like Ozempic®) are not provided in the sources, the trend indicates significant growth. Semaglutide, for instance, is among the top medications in terms of spend, and its increased indications and approvals are likely to drive higher prices and demand[2].
Competitive Analysis
The market is highly competitive, with major players such as Novo Nordisk, Eli Lilly and Company, and AstraZeneca Plc. These companies engage in extensive marketing and educational campaigns, as well as partnerships with healthcare providers, to increase awareness and adoption of their products[1][4].
Market Segmentation
The incretin-based drugs market is segmented by drug type (GLP-1 receptor agonists and DPP-4 inhibitors), formulation, route of administration, and distribution channel. Understanding these segments helps in identifying prevailing market opportunities and growth strategies[1][4].
Challenges and Restraints
Despite the growth, the market faces several challenges:
High Cost and Safety Concerns
The high cost of treatment and increased safety concerns are significant restraints. The absence of supportive reimbursement policies and lack of accessibility to these drugs in some regions also negatively impact market growth[4].
Regulatory and Transparency Issues
Prescription drug price transparency programs, such as Oregon's, highlight the complexities and variability in drug pricing. These programs aim to provide accountability but face challenges in gathering comprehensive data due to trade secrets and compliance issues[5].
Key Takeaways
- The global incretin-based drugs market is projected to grow significantly, driven by the rising prevalence of type 2 diabetes and expanding indications for GLP-1 agents.
- The Asia-Pacific region is expected to be the fastest-growing segment due to increasing healthcare expenditure and developing healthcare infrastructure.
- Drug price inflation, including for semaglutide, is anticipated to continue, driven by expanding indications and increased spend.
- The market faces challenges such as high treatment costs, safety concerns, and regulatory transparency issues.
FAQs
What is the projected market size of the global incretin-based drugs market by 2032?
The global incretin-based drugs market is projected to reach $73.9 billion by 2032[1].
What are the key drivers of the incretin-based drugs market growth?
The key drivers include the rising prevalence of type 2 diabetes, expanding indications for GLP-1 agents, and increasing healthcare expenditure, particularly in the Asia-Pacific region[1][2].
Which region is expected to be the fastest-growing segment for incretin-based drugs?
The Asia-Pacific region is anticipated to be the fastest-growing segment during the forecast period[1].
How does drug price inflation impact the incretin-based drugs market?
Drug price inflation, estimated at 3.81% for 2025, is partly driven by the expanding indications of previously approved medications like semaglutide, leading to higher spend and demand[2].
What are the major challenges facing the incretin-based drugs market?
The major challenges include high treatment costs, safety concerns, absence of supportive reimbursement policies, and lack of accessibility to these drugs in some regions[4].
Sources
- Allied Market Research - Incretin-Based Drugs Market Statistics, Forecast - 2032
- Vizient Inc. - Vizient projects drug price inflation at 3.81%
- GlobeNewswire - U.S. OTC Drugs Market Forecast Report 2024-2029
- Zion Market Research - Global Incretin-Based Drugs Market Size, Share, Growth & Forecast
- Oregon Department of Consumer and Business Services - Prescription Drug Price Transparency Results and Recommendations
More… ↓
